Immunocore and Pierre Fabre have been representing Europe in this years’ Society for Melanoma Research Congress. This type of cancer may have its days counted!
This week, scientists from around the globe met at the MRC to get an update on what’s going on in the fights against melanoma, the least common but most deadly skin cancer. Immunocore and Pierre Fabre, European representatives, put up a strong show by reporting positive results in clinical trials.
Immunocore, one of the 3 European unicorns and the company with the biggest financing round in European Biotech ever, targets melanoma with its revolutionary T-cell receptor (TCR)-based ImmTAC technology. The company has reported that IMCgp100, its lead candidate, has shown activity and favorable safety in Phase I trials for uveal melanoma. Phase II trials for cutaneous melanoma are also being carried out.
The news is exciting because these are some of the first results presented by Immunocore, whose technology can reduce costs as compared to other promising immuno-oncology therapies like CAR-T.